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Abstract 
Foxp3
+ regulatory T lymphocytes (Tregs) usually act as an immune suppressor and correlate 
with poorer survival in malignancies. This study aims to investigate the distribution and 
characterization of Foxp3
+ subset in peripheral blood mononuclear cells (PBMCs) and tumor 
tissues from extranodal NK/T cell lymphoma (ENKTL). Our study showed the percentage of 
Foxp3
+ subset from PBMC was significantly higher than that of healthy individuals (P<0.001). 
The Foxp3
+ subset from PBMCs expressed CD45RO, CTLA4, GITR, CCR7, and had an 
IL-10
highIFN
+TGF
+IL-2
lowIL-17
low cytokine secreting phenotype. Interestingly, the existence 
of EBV antigen-specific CD8
+Foxp3
+ Tregs was discovered in ENKTL. Furthermore, the high 
density of Foxp3
+ TILs was associated with improved progression-free survival (PFS) in 
ENKTL patients (P<0.05). Collectively, our study implicates that EBV antigens could induce 
antigen-specific CD8
+Foxp3
+ Tregs in ENKTL, and Foxp3
+ TILs is an independent factor for 
PFS in ENKTL. 
Key words: Foxp3+ regulatory T cells; Extranodal NK/T cell lymphoma; tumor infiltrating lym-
phocytes; EBV 
Introduction 
Extranodal NK/T-cell lymphoma (ENKTL), na-
sal  type  referred  to  as  angiocentric  lymphoma  ac-
cording to the REAL classification[1], is recognized as 
a distinctive clinicopathologic entity and Epstein-Barr 
virus (EBV) associated disease. A typical phenotype of 
ENKTL is CD2+, CD3+, CD56+, cytotoxic molecules 
positive and EBV encoded RNA (EBERs) positive[2]. 
ENKTL patients are often refractory to radiotherapy 
and  chemotherapy,  and  show  aggressive  behaviors 
with poor outcomes. EBV is presented in the malig-
nant cells of ENKTL as latent type II infection, irre-
spective of geographical origin[3], and infiltration of 
reactive inflammatory cells, including small lympho-
cytes, plasma cells, and histiocytes for the neo-virus 
antigens  expressed  on  malignant  cells  are  dectect-
ed[2]. However, it is still poorly understood the role of 
specific circulating and tumor infiltrating lymphocyte 
subsets in the disease progression of ENKTL. 
CD8+  cytotoxic  T  lymphocytes  (CTLs)  play  a 
major  role  in  controlling  and  eradicating  the  vi-
rus-infected cells, and the density of CD8+ TILs is as-
sociated with prognosis of patients with cancers[4-8]. 
Furthermore,  the  responses  of  CD4+  T  cell  to  viral 
infections  are  critical  to  maintain  virus-specific 
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memory CTLs[9]. CD4+ T cells are comprised of the 
traditional Th1, Th2 helper T cell subsets, Foxp3+ reg-
ulatory  T  cell  (Tregs)  and  IL-17-producing  Th17 
cells[9]. For the suppressive function to immune re-
sponse  and  maintenance  the  immune  tolerance, 
Foxp3+ Tregs is usually identified as a suppressor to 
anti-tumor  immunity  and  associated  with  poorer 
clinical  outcome  of  patients  with  some  solid  tu-
mors[10-12].  However,  recently  studies  suggested 
that  the  density  of  tumor  infiltrating  Foxp3+  Tregs 
was  associated  with  improved  outcome  of  patients 
with  EBV  positive  malignancies  including  Hodgkin 
lymphoma,  nasopharyngeal  carcinoma  (NPC)  and 
other cancer, such as follicular lymphoma[8, 13, 14], 
but it is still unclear for the distribution and charac-
terization  of  Tregs  and  its  association  with  clinical 
outcome in patients with EBV positive ENKTL. In this 
study, to identify the Foxp3+ Tregs subset in circulat-
ing lymphocytes and tumor tissues in patients with 
ENKTL,  we  investigated  the  biological  features  of 
Foxp3+  Tregs  subset  in  PBMCs,  and  the  correlation 
with  the  density  of  different  lymphocyte  subset  in-
cluding  CD4+  TILs,  CD8+  TILs  and  Foxp3+  TILs  in 
tumor  tissues  and  clinicopathological  characteristics 
and survival of ENKTL patients.  
Materials and Methods 
Patients 
Thirty-five newly diagnosed ENKTL cases were 
included in this study, peripheral blood was collected 
from 10 patients and 10 age-matched healthy donors 
for  isolating  lymphocytes,  and  paraffin-embedded 
specimen were collected from 27 cases at Sun Yat-Sen 
University Cancer Center from 2001 to 2009. Tumor 
tissue and paired blood were obtained from two cas-
es. Informed consent was obtained from each subject. 
This  study  was  conducted  in  accordance  with  the 
Helsinki Declaration, and approved by the Research 
Ethic  Committee  of  Sun  Yat-Sen  University  Cancer 
Center. All healthy donors provided written informed 
consent for their participation. 
All patients followed the criteria described in the 
previous  report[15].  The  demographic  characteristic 
of  all  eligible  patients  was  showed  in  Table  1  and 
Supplementary  Material:  Table  S1.  There  were  25 
males and 10 females in 35 eligible cases. The median 
age was 41 years (Range 13-68 years). Twelve patients 
(34.3%) had B symptom and 22 cases were localized 
disease (Ann Arbor stage I and II, 62.8%). Most cases’ 
performance  status  was  0-1  (n=26,  74.3%)  and  the 
remains’ were 2-4 (n=9, 25.7%). The disease primarily 
involved  the  upper  aerodigestive  tract  (UAT)  in  24 
cases (68.6%) and non-UAT in 11 cases (31.4%); and 16 
cases  (45.7%)  had  elevated  serum  lactate  dehydro-
genase  (LDH).  Seventeen  cases  were  categorized  as 
0-1 and  18  cases  as 2-5  for  International  Prognostic 
Index (IPI). Thirteen cases (37.1%) were low risk, the 
other  22  cases  (62.9%)  were  in  intermediated  or 
high-risk  group,  based  on  Korean  Prognostic  Index 
(KPI); while 25 cases (71.4%) were low risk, and the 
other 10 cases (28.6%) were intermediated to high risk, 
according to peripheral T cell prognostic index (PIT) 
model. All cases in this study were EBV positive by 
EBERs (EBV encoding RNAs, EBERs) in situ hybridi-
zation. 
Table 1. Clinical charactertics of 35 cases of newly diag-
nosed extranodal NK/T cell lymphoma 
Characteristics  Case (%) 
Gender   
Male  25 (71.4) 
Female  10 (28.6) 
Age   
Median  41 
Range  13-68 
B symptom   
No  23 (65.7) 
Yes  12 (34.3) 
Performance status   
0-1  26 (74.3) 
≥2  9 (25.7) 
Involved field   
UAT  24 (68.6) 
non-UAT  11 (31.4) 
Ann-Arbor Stage   
I  7 (20.0) 
II  15 (42.8) 
III  5 (14.3) 
IV  8 (22.9) 
LDH   
Normal  19 (54.3) 
Elevated  16 (45.7) 
IPI score   
0-1  17 (48.5) 
2-5  18 (51.5) 
KPI score   
0-1  13 (37.1) 
2-4  22 (62.9) 
PIT score   
0-1  25 (71.4) 
2-4  10 (28.6) 
Note: UAT, upper aerodigestive tract; LDH, lactate dehydrogenase; 
IPI, International Prognostic Index; KPI, Korean Prognostic Index; 
PTI: Peripheral T-cell lymphoma Prognostic Index Int. J. Biol. Sci. 2011, 7 
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Antibodies and flow cytometer analysis 
(FACS) 
The following antibodies were used for staining 
single  cell  suspension  ex  vivo:  anti-CD4  (Clone 
RPA-T4),  anti-CD25  (BC96),  anti-CCR6  (R6H1),  an-
ti-IL17 (SCPL1362), anti-FOXP3 (236A/E7), anti-IFN 
(B27),  anti-IL-2  (M11-17H12),  anti-IL-10  (JES3-19F1), 
anti-CCR7 (3D12), anti-CD45RO (HI100), anti-CTLA-4 
(eBio20A) and anti-GITR (eBioAITR) antibodies con-
jugated  with  FITC,  PE,  APC  or  PE-Cy7  were  pur-
chased from BD Biosciences (San Jose, CA, USA) or 
eBioscience (San Diego, CA, USA). Recombinant hu-
man IL-2 was purchased from R & D System (Boston, 
MS, USA).  
The expression of markers on T cells was inves-
tigated by FACS analysis after surface staining or in-
tracellular  staining  with  anti-human-specific  Abs 
conjugated  with  different  fluorescence  dyes.  Intra-
cellular  staining  for  cytokines  was  performed  on  T 
cells  stimulated  by  phorbol12-myristate13-acetate 
(PMA) and inomycin in the presence of brefeldin A 
(10  g/ml,  Sigma-Aldrich)  for  4  hours.  Cells  were 
stained with  fluorescent antibodies in 0.1% saponin 
permeablization buffer and detected on a FC500 flow 
cytometer  machine.  All  data  were  analyzed  using 
CXP analysis software (Beckman Coulter, Inc. Fuller-
ton, CA, USA). 
The frequency of T cell specific for HLA-A2 re-
stricted epitopes in LMP1 and LMP2 was analyzed by 
staining  with  HLA-A2  tetramers  assembled  with 
synthetic peptides origin from LMP1 YLQQNWWTL 
and LMP2 FLYALALLL, LLWTLVVLL, GLGTLGAAI 
(Guangzhou Taimo Corporation, Guangzhou, China). 
The  samples  were  stained  with  1  g/ml  phyco-
erythrin (PE)-labeled tetrameric complex firstly, and 
then  co-stained  with  anti-CD8-FITC  and  an-
ti-Foxp3-APC antibodies followed by fixation in 0.5% 
paraformaldehyde for 20 mins. For each sample, 105 
cells were analyzed using the FC500 flow cytometer 
machine and CXP analysis software. 
CD4-positive and CD8-positive Tregs sorting 
and T cell proliferation 
CD4+CD25+ Tregs  or  CD8+CD25+ Tregs  subsets 
from  PBMCs  of  ENKTL  were  isolated  with  the  an-
ti-CD4, anti-CD8 and anti-CD25 staining and FACS 
sorting  on  FACS  sorting  machine  MoFlo  XDP  Cell 
Sorter  (Beckman  Coulter,  Inc.  Fullerton,  CA,  USA). 
The  sorted  cells  were  expanded  in  IL-2  medium  in 
vitro, and T cell proliferation assays were performed 
as described previously[16]. In brief, 105 CD4+ naïve T 
cells  were  labelled  with  5-  or 
6-(N-Succinimidyloxycarbonyl)-3',6'-O,O'-diacetylflu
orescein  (CSFE,  Molecular  Probes/Invitrogen,  Bur-
lington, CA) and cocultured with different ratios of 
CD4+ Tregs cells in u-bottom 96-well human OKT-3 
(1ug/ml) coated plate for 5 days in no IL-2 medium. 
The proliferation of CSFE-labeled CD4+ naïve T cells 
was  detected  by  FACS  analyses  gating  on  the 
CSFE-labelled cell population.  
Immunohistochemical staining (IHC) 
The  paraffin-embedded  tumor  sections  were 
used for IHC. After antigen retrieval by microwave 
heating (95°C for 20 min), tissue sections were incu-
bated  with  primary  antibodies  including  mouse 
monoclonal  anti-human  CD4  (Clone  4B12,  DAKO, 
Glostrup,  Denmark;  diluted  at  1:80),  mouse  mono-
clonal  anti-human  CD8  (Clone  CD8/144B,  DAKO, 
Glostrup,  Denmark;  diluted  at  1:40),  mouse  mono-
clonal anti-human Foxp3 (Clone 221D/D3, Santa Cruz 
Biotechnology,  CA,  USA,  diluted  at  1:100),  mouse 
monoclonal anti-LMP2A was provided by Prof. Zeng 
M (diluted at 1:200)[17] were incubated at 4°C over-
night. Then bind to non-biotin horseradish peroxidase 
detection  system  (Dako,  Glostrup,  Denmark).  Data 
was  obtained  by  counting  the  positively  stained 
lymphocytes  in  5  separate  400×  high-power  micro-
scopic fields (HPFs) and calculating the mean number 
of  positively  stained  cells  per  HPF.  Mouse  IgG1 
(DAKO, Glostrup, Denmark) negative control stain-
ing was generated and evaluated. LMP2A expression 
was  defined  as  negative  for  score  0-2,  positive  for 
score 3-5, according to the number  and intensity of 
stained cell.  
Statistical analysis 
All data was analyzed with SPSS 16.0 software 
(SPSS, Chicago, IL, USA). The median value was ap-
plied  to  cut  off  the  subgroups  of  all  immunohisto-
chemical  variants  in  our  data.  The  correlation  with 
lymphocytic variables and clinical characteristics was 
estimated by Pearson chi test or Fisher’s Exact test. 
Two-tailed P<0.05 was set as statistical significance. 
Survival  rate  was  calculated  by  the  Kaplan-Meier 
method and tested by the log-rank analysis. Cox re-
gression analysis was applied to adjusted analysis. 
Results 
Increased proportion of circulating 
CD4+Foxp3+ Tregs and CD8+Foxp3+ Tregs was 
determined in ENKTL patients 
To identify the Foxp3+ Treg subset in peripheral 
blood  of  ENKTL  patients,  we  firstly  compared  the 
proportion of Foxp3+ Tregs in CD4+ and CD8+ subsets 
in PBMCs from ENKTL patients and controls (healthy 
individuals) by FACS analyses based on the expres-Int. J. Biol. Sci. 2011, 7 
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sion of Foxp3 protein. As shown in Fig 1A and 1B, the 
percentage  of  CD4+Foxp3+ Tregs  (mean=9.00±7.61%; 
n=10)  and  of  CD8+Foxp3+ Tregs  (mean=8.97±6.17%; 
n=10)  in  PBMCs  from  ENKTL  patients  was  signifi-
cantly higher compared to that of in healthy individ-
uals  (mean=0.75±0.43%  and  mean=0.48±0.44%,  re-
spectively; n=20, both P<0.001). 
Next we sought to explore the phenotypic and 
functional features of Foxp3+ Tregs subset in PBMCs 
of  ENKTL  patients.  The  Foxp3+  Tregs  subset  ex-
pressed high level of CD45RO and middle levels of 
CCR7, CTLA4 and GITR that indicated most Foxp3+ 
Tregs in ENKTL were from memory cell population 
and expressed the special markers CTLA4 and GITR 
for Tregs (Fig 2A). The cytokine expression profiles of 
the Foxp3+ Tregs subset expressed high levels of IL-10 
and TGF, low levels of IL-2 and IL-17 (Tregs pheno-
type). Interestingly, the level of IFN- in Foxp3+ Tregs 
subset in PBMCs from ENKTL was much higher than 
that  of  in  PBMCs  from  healthy  donors  (data  not 
shown). In order to test the suppressive function of 
Tregs  subset  in  PBMCs  from  ENKTL  patients,  we 
sorted  the  CD4+CD25high  and  CD8+CD25high  subsets 
and  expanded  these  two  cell  subsets  in vitro.  Cells 
expressing high levels of CD25 in PBMCs were usu-
ally qualified as Tregs in this study followed others’ 
report[18]. The suppressive ability of these two sub-
sets to CD4+ naïve T cells in vitro was detected after 
expansion in vitro. Both CD4+CD25+ T cell subset and 
CD8+CD25+ T cell subset could inhibit the prolifera-
tion of CD4+ naïve T cells shown in Fig 2B. 
The EBV LMP1 and LMP2 epitopic anti-
gen-specific CD8+ effectors and CD8+Foxp3+ 
Tregs was identified in ENKTL patients 
The ENKTL tumor cells can express EBV latent 
type II antigens including LMP1, LMP2, EBNA1 and 
BARF0 as nasopharyngeal carcinoma or EBV positive 
B cell lymphoma[19, 20]. In order to address if there 
are pathogenic CD8+ Treg cells as well as CD8+ effec-
tor T cells induced by EBV antigens in ENKTL, we 
detected the HLA-A2 restricted EBV LMP1 (YLQ) and 
LMP2 (FLY, GLG and LLW) epitopic antigen-specific 
effector T cells and Foxp3+ Tregs in PBMCs from five 
HLA-A2 positive ENKTL patients and five HLA-A2 
positive  healthy  controls  by  CD8  with  tetramer 
staining together and CD8 and Foxp3 with tetramer 
staining  together.  We  found  out  the  different  fre-
quency of CD8+tetramer+ LMP1 (YLQ) or LMP2 (FLY, 
GLG and LLW) epitopic effector T cells in circulating 
blood  from  five  ENKTL  patients  and  five  healthy 
controls as shown in Fig 3A and B; Interestingly, we 
also  measured  that  the  different  frequency  of 
CD8+Foxp3+tetramer+ Treg cells in circulating blood 
from the same five ENKTL patients but not in healthy 
controls as shown in Fig 3C and 3D.  
 
 
Figure 1. The distribution of CD4
+Foxp3
+ Tregs and CD8
+Foxp3
+ Tregs in PBMCs of ENKTL patients and healthy donors. 
A. Representative dot plots for CD4, Foxp3 and CD8, Foxp3 in PBMCs from 2 ENKTL patients and 2 health donors. B. The 
dramatically increase of CD4
+Foxp3
+ Tregs and CD8
+Foxp3
+ Tregs was found out in PBMCs of ENKTL (n=10) compared 
with that of in PBMCs of healthy donors (n=10, P<0.005).  Int. J. Biol. Sci. 2011, 7 
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Figure 2. The biological characteristics and function of Foxp3
+ Tregs subset. A. The flow cytometer profiles are repre-
sentatives from the stainings for CTLA, GITR, CD45RO, CCR7, IFN, IL-2, IL-17, IL-10 and TGF in Foxp3
+ Treg subset. B. 
The suppressive ability of CD4
+ Tregs and CD8
+ Tregs to naïve CD4
+ T cells in vitro was measured by the T cell proliferation 
experiment. CSFE-labeled naïve CD4
+ T cells were alone or co-cultured with CD8
+ Tregs cells at ratio of 1:1 in the in 
complete RPMI1640 medium without IL-2 in OKT3-coated 96-well plate for 5 days and analyzed by FACS detection. 
 
 
The correlation of different tumor infiltrating 
lymphocyte subset and clinicopathological 
parameters was analyzed in ENKTL patients. 
There  are  large  amount  of  inflammatory  cells 
around the tumor tissues in ENKTL for the presenta-
tion of neo-virus antigens on EBV infected tumor cells 
in ENKTL[2]. To characterize the lymphocyte subsets 
of TILs in ENKTL tumor tissues, we defined the dif-
ferent lymphocyte subset by specific antibodies: CD4 
for helper T lymphocytes, CD8 for effector T cells and 
Foxp3  for  Tregs  (Fig  4A).  The  median  number  of 
CD4+,  CD8+  and  Foxp3+  cells  in  tumor  tissues  was 
15.28±3.33  cells/HPF  (range  0-62),  54.31±8.60 
cells/HPF  (range  0-212),  and  22.89±4.69  cells/HPF 
(range  0-100)  respectively  (Supplementary  Material: 
Table S2).  
The correlations of the number of TILs subsets 
and clinicopathological parameters were summarized 
in Table 2. In brief, the density of CD4 was signifi-
cantly negatively related to Korean Prognostic Index 
(KPI)  and  International  Prognostic  Index  (IPI) 
(P<0.05), and marginally related to Ann Arbor stage 
(P=0.09).  Interestingly,  the  density  of  Foxp3+  Tregs 
was negatively correlated with Ann Arbor stage and 
serum  LDH  (P<0.05).  And  it  seemed  relate  to  KPI, 
though it was not significant (P=0.06). These data in-
dicated that the density of CD4+ T cells and Foxp3+ 
Tregs  both  was  negatively  associated  to  other  risk 
prognostic  factors  in  ENKTL.  No  significant  rela-Int. J. Biol. Sci. 2011, 7 
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tionship  was  observed  between  the  density  of  CD8 
and ENKTL clinical characteristics (P>0 .05). And no 
association was found between the density of differ-
ent  TILs  subsets  and  the  expression  of  LMP2A  on 
tumor cells in ENKTL (P>0.05).  
Increased Foxp3+ TILs predicts a favorable 
progression-free survival in ENKTL patients 
Twenty-seven newly diagnosed cases with tissue 
sections  were  performed  for  survival  analysis.  The 
estimated 3-year survival rate was 20.0% and median 
survival time was 13.1 months (4.1-116.5 months) in 
this study group. Seventeen cases died of cancer at the 
last  follow-up  and  19  cases  relapsed  (data  listed  in 
Supplementary Material: Table S2). A higher density 
of  Foxp3  Tregs  (>22.89  cells/HPF)  correlated  with 
better  overall  survival  (OS)  (HR,  0.32;  95%  CI, 
0.10-0.98;  P=0.046,  Table  3  and  Fig  4B),  and  longer 
progression-free survival (PFS) by univariate analysis 
(HR, 0.31; 95% CI, 0.11-0.85; P=0.024, Table 3 and Fig 
4C). Moreover the number of Foxp3 remained an in-
dependent  predictor  for  PFS  (HR,  0.12;  95%  CI, 
0.02-0.91;  P=0.040,  Table  3)  after  adjusted  multiple 
variates  analysis  combined  with  other  classical  risk 
prognostic  factors  including  Ann  Arbor  stage,  B 
symptom, performance status, serum LDH level, IPI, 
KPI and PIT. But Foxp3 failed to predict OS of ENKTL 
patients (HR, 0.18; 95% CI, 0.05-1.75; P=0.997, Table 3) 
in  adjusted  analysis.  The  density  of  CD4  and  CD8 
didn’t predict the OS and PFS in this study (P>0.05). 
Data was outlined in Table 3.  
 
 
Figure 3. The identification of EBV-LMP1 and LMP2 epitopic antigen-specific CD8
+ T cells and CD8
+Foxp3
+ Tregs in 
ENKTL patients. A. FACS analysis of HLA-A2 restricted EBV epitopic antigen LLW, YLQ (LMP1) and GLG (LMP2) antigen 
specific CD8
+ T cells; B. The histogram showed different percentage of CD8
+tetramer
+ T cells in PBMCs from HLA-A2 
positive ENKTL patients (n=5) and healthy controls (n=5); C. FACS analysis of HLA-A2 restricted EBV epitopic antigen 
LLW, YLQ (LMP1) and GLG (LMP2) antigen-specific CD8
+Foxp3
+ Tregs; D. The histogram showed different percentage of 
CD8
+Foxp3
+tetramer
+ Tregs in PBMCs from HLA-A2 positive ENKTL patients (n=5) and healthy controls (n=5). Int. J. Biol. Sci. 2011, 7 
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Figure 4. The expression of CD4, CD8 and Foxp3 in TILs and LMP2 in tumor cells of ENKTL patients and results of survival 
rate with Foxp3+ TILs in ENKTL patients. A, Immunohistochemical staining of CD4, CD8, Foxp3 in TILs and LMP2A was 
performed in tumor section of ENKTL patients (n=27). CD4 (A-1) and CD8 (A-2), LMP2A (A-3), Foxp3 (A-4) and isotypic 
antibody negative control (A-5). The number of Foxp3+ TILs are significantly associated with the overall survival (C, 
P=0.046) and progression-free survival (D, P=0.024) in ENKTL patients. 
 
Table 2. The association of immunohistochemical variants and clinicpathological characteristics of 27 cases of ENKTL with 
tissue sections 
Characteristics  CD4  P value  CD8  P value  FOXP3  P value 
≤ 15.28  > 15.28  ≤ 54.31  > 54.31  ≤ 22.89  > 22.89 
Age      1.00      0.50      0.19 
  < 60  17 (63.0)  8 (29.6)    14 (51.9)  11 (40.7)    15 (55.6)  10 (37.0)   
  ≥ 60  2 (7.4)  0    2 (7.4)  0    0  2 (7.4)   
Gender      1.00      1.00      0.63 
  Male  15 (55.6)  7 (25.9)    13 (48.1)  9 (33.3)    13 (48.1)  9 (33.3)   
  Female  4 (14.8)  1 (3.7)    3 (11.1)  2 (7.4)    2 (7.4)  3 (11.1)   
Stage      0.09      0.43      *0.005 
  I-II  9 (33.3)  7 (25.9)    8 (29.6)  8 (29.6)    5 (18.5)  11 (40.7)   
  III-IV  10 (37.0)  1 (3.7)    8 (29.6)  3 (11.1)    10 (37.0)  1 (3.7)   
B symptom      1.00      0.24      0.44 
  No  11 (40.7)  4 (14.8)    7 (25.9)  8 (29.6)    7 (25.9)  8 (29.6)   
  Yes  8 (29.6)  4 (14.8)    9 (33.3)  3 (11.1)    8 (29.6)  4 (14.8)   Int. J. Biol. Sci. 2011, 7 
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Characteristics  CD4  P value  CD8  P value  FOXP3  P value 
≤ 15.28  > 15.28  ≤ 54.31  > 54.31  ≤ 22.89  > 22.89 
LDH      0.21      0.70      *0.05 
  Normal  8 (29.6)  6 (22.2)    9 (33.3)  5 (18.5)    5 (18.5)  9 (33.3)   
  Elevated  11 (40.7)  2 (7.4)    7 (25.9)  6 (22.2)    10 (37.0)  3 (11.1)   
PS      0.68      0.69      0.22 
   0-1  12 (44.4)  6 (22.2)    10 (37.0)  8 (29.6)    8 (29.6)  10 (37.0)   
   2-5  7 (25.9)  2 (7.4)    6 (22.2)  3 (11.1)    7 (25.9)  2 (7.4)   
IPI score      *0.03      0.71      0.13 
  0-1  5 (18.5)  6 (22.2)    6 (22.2)  5 (18.5)    4 (14.8)  7 (25.9)   
  2-5  14 (51.9)  2 (7.4)    10 (37.0)  6 (22.2)    11 (40.7)  5 (18.5)   
KPI score      *0.03      0.45      0.06 
  0-1  4 (14.8)  6 (22.2)    7 (25.9)  3 (11.1)    3 (11.1)  7 (25.9)   
  2-4  15 (55.6)  2 (7.4)    9 (33.3)  8 (29.6)    12 (44.4)  5 (18.5)   
PIT score      0.67      1.00      0.42 
  0-1  11 (40.7)  6 (22.2)    10 (37.0)  7 (25.9)    8 (29.6)  9 (33.3)   
  2-4  8 (29.6)  2 (7.4)    6 (22.2)  4 (14.8)    7 (25.9)  3 (11.1)   
LMP2A      0.36      1.00      1.00 
 Negative  5 (20.8)  4 (16.7)    5 (20.8)  4 (16.7)    4 (16.70  5 (20.8)   
 Positive  12 (50.0)  3 (12.5)      9 (37.5)  6 (25.0)      8 (33.3)  7 (29.2)     
Note: UAT, upper aerodigestive tract; LDH, lactate dehydrogenase; IPI, International Prognostic Index; KPI, Korean Prognostic Index; PTI: 
Peripheral T-cell lymphoma Prognostic Index; PS: performance status. 
 
Table 3. Prognostic value of TIL variants for OS and PFS in 27 cases of newly diagnosed ENKTL with tissue sections 
Parameter  Overall survival    Progress-free survival 
Univariate analysis    Adjusted analysis    Univariate analysis    Adjusted analysis 
HR  95% CI  P-value    HR  95% CI  P-value    HR  95% CI  P-value    HR  95% CI  P-value 
CD4  0.67  0.22-2.06  0.480     1.00   0.15-6.63  0.626    0.44  0.14-1.32  0.142    0.54  0.10-3.01  0.484 
CD8  0.57  0.20-1.66  0.300     1.70   0.20-14.52  0.182    0.51  0.19-1.38  0.188    0.47  0.06-3.56  0.465 
FOXP3  0.32  0.10-0.98  *0.046     0.18   0.05-1.75  0.997     0.31  0.11-0.85  *0.024     0.12  0.02-0.91  *0.040 
Note: Adjusted analysis included Ann-Arbor stage, performance status, LDH, B symptom, IPI, KPI and PIT 
 
 
Discussion  
Increased  CD4+CD25+  Tregs  or  CD4+Foxp3+ 
Tregs  in  peripheral  blood  has  been  reported  in  pa-
tients with cancers including gastric cancer, colorectal 
cancer, glioma and NPC[8, 21-23]. We not only inves-
tigated  the  significantly  increased  frequency  of 
CD4+Foxp3+ Tregs in circulating lymphocyte, but also 
detected  the  dramatically  increased  frequency  of 
CD8+Foxp3+ Tregs in circulating lymphocytes of pa-
tients with EBV positive ENKTL compared to healthy 
donors  (P<0.001,  Fig  1A  and  B).  The  expansion  of 
CD8+ Tregs in peripheral blood has been reported in 
lung  cancer  and  pleural  mesothelioma[24],  our  re-
cently work also showed the significantly increased 
frequency  of CD8+ Tregs in peripheral blood of pa-
tients  with  EBV  positive  NPC  (un-published  data). 
The  phenotypes  and  functional  features  of  Foxp3+ 
Tregs subset were observed in this study. The Foxp3+ 
Tregs subset highly expressed CD45RO molecule and 
some  levels  of  CCR7,  GITR  and  CTLA4,  and  ex-
pressed  IL-10highIFN+TGF+IL-2lowIL-17low  cytokine 
secreting phenotype (Fig 2A), indicating that Foxp3+ 
Tregs  subset  in  PBMCs  from  ENKTL  patients  con-
tained different Treg cell subset such as natural Tregs 
(nTreg) and T regulatory Type 1 cells (Tr1 cells) which 
usually with a IL-10highTGF+IFN+IL-2- cytokine se-
creting  phenotype.  The  suppressive  function  of 
Foxp3+ Tregs in ENKTL was determined in this study 
by inhibiting the proliferation of naïve T cells using 
the CD4+CD25high cells and CD8+CD25high sorting cells 
population  in  vitro  (Fig  2B).  However,  here  we 
couldn’t find out the correlation of increased propor-
tion of Foxp3+ Tregs subset in PBMCs and the tumor 
progression of ENKTL for limitation of sample num-
ber (only 10 ENKTL patients). The frequency of Tregs 
in peripheral blood increased with tumor stage has 
been reported in gastrointestinal malignancies[22]. Int. J. Biol. Sci. 2011, 7 
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EBV infection is associated with lymphoid and 
epithelial origin cancers including Burkitt lymphoma, 
Hodgkin lymphoma, nasopharyngeal carcinoma and 
ENKTL[25,  26].  The  presentation  of  neo-virus  anti-
gens  by  virus-infected  tumor  cells  could  trigger  an 
enlarged  cellular  immune  response  in  cancer  pa-
tients[27-31]. However, the tumor cells still escape the 
supervision  of  immune  system,  and  the  pathogenic 
induced Tregs has been identified in cancer in addi-
tion  to  the  pathogenic  specific  cytotoxic  T  cell[32]. 
Here, we discovered for the first time that the exist-
ence  of  EBV  LMP1  and  LMP2  HLA-A2  restricted 
epitopic antigen-specific CD8+ Tregs in PBMCs from 
ENKTL patients (Fig 3C and 3D) in addition to the 
existence of EBV LMP1 and LMP2 HLA-A2 restricted 
epitopic antigen-specific cytotoxic T cells (Fig 3A and 
3B); but we only found out the EBV antigen-specific 
effector  T  cells  not  the  EBV  antigen-specific 
CD8+Foxp3+ Tregs in healthy donors. The similar re-
sults  were  also  found  in  NPC  patients  (data  not 
shown) recently. These data suggest that the EBV can 
induce virus antigen-specific Tregs besides the EBV 
antigen-specific  effector  T  cells  in  ENKTL  patients. 
But we failed to find out the correlation of the density 
of TILs subsets including  Foxp3+ Tregs and the ex-
pression of LMP2 antigen on tumor cell in this study. 
Foxp3+ Tregs subset as suppressors of activated 
T effector cells usually have suppression to anti-tumor 
immunity in malignancies and correlated with poorer 
survival in many kinds of solid cancers[33]. However, 
recently  in  EBV  associated  malignancies  including 
nasopharyngeal  carcinoma,  EBV  positive  classic 
Hodgkin lymphoma and follicular lymphoma, higher 
number  of  Foxp3+  TILs  was  associated  with  better 
survival[8, 13, 14]. ENKTL is an EBV positive malig-
nancy with distinctive clinical symptoms and aggres-
sive progression. Several classical prognostic factors 
including LDH level, B symptoms, IPI, PIT, and KPI 
could predict the prognosis of ENKTL patients. Re-
cently one research group observed that the increas-
ing number of absolute lymphocytes count (ALC) is a 
novel favorable prognostic index for ENKTL[15]. But 
it is still unclear the association of specific lympho-
cytes subset and clinical features and outcome, and 
their biological function in ENKTL. Here, our results 
showed that the density of CD4+ TILs was negatively 
associated with IPI and KPI score that suggested the 
CD4+ TILs decreased in high risk patients. Moreover 
the number of Foxp3+ TILs was negatively correlated 
with Ann Arbor stage and LDH level that implicated 
the frequency of Foxp3+ TILs was high in early stage 
and low tumor burden of ENKTL patients (Table 2). 
We cut off 27 newly diagnosed ENKTL patients into 
two  subgroups  by  the  median  density  of  Foxp3+ 
TILs/HPF (22.89 cells/HPF), the ENKTL group with 
higher number of Foxp3+ TILs has longer OS and PFS, 
and moreover Foxp3 is an independent factor for PFS 
by adjusted multiple variates survival analysis (Table 
3).  Our  findings  were  consistent  with  Kim’s  re-
port[34]. Until now it is difficult to explain the clinical 
correlation and biological function of Foxp3+ Tregs in 
tumor site. The impact of Foxp3+ Tregs on tumor cells’ 
behavior and on patients’ outcome was conflicting in 
different type of malignancies. In EBV positive NPC 
patients we also found the Foxp3+TILs was an inde-
pendent  factor  for  prolonged  OS  and  PFS[8],  and 
moreover the Foxp3+ Tregs from tumor tissues could 
secret  a  large  amount  of  IFN  compared  to  that  of 
PBMCs  in  the  paired  NPC  patients  (un-published 
data). Here, we also found that the Foxp3+Tregs sub-
set  in  PBMCs  of  ENKTL  patients  contained  a  high 
proportion of IFN-secreting cells; the IFN is an in-
flammatory cytokine which could inhibit the growth 
of tumor cells, maybe Foxp3+ TILs take a protective 
function through secreting Th1 cytokine IFN. How-
ever, we couldn’t detect this function of Tregs subset 
from TILs for the limitation of the small biopsy tumor 
tissues of ENKTL.  
In summary, this study revealed for the first time 
the increased proportion of Foxp3+ Tregs in CD4+ and 
CD8+ cells population in peripheral blood of ENKTL 
patients compared with healthy individuals, and the 
Foxp3+  Tregs  subset  in  PBMCs  expressing 
IL-10highIFN+TGF+IL-2lowIL-17low  cytokine  secreting 
phenotype.  Interestingly,  we  identified  for  the  first 
time that the EBV could  induce pathogenic antigen 
specific Tregs subset in ENKTL patients. At last, we 
illustrated that the increase of Foxp3 Trges in tumor 
tissues was an independent favorable prognostic in-
dex for PFS in ENKTL. 
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